Clinical trial
A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus
NCT02437890 is registered in ClinicalTrials.gov with Ablynx, a Sanofi company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus
- Lead sponsor
- Ablynx, a Sanofi company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2015
- Completion date
- January 31, 2018
- Enrollment
- 312 (actual)
- Sites
- 118
Conditions
As the registry lists them; a condition with its own page is linked.